Trials / NCT01786395
Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
Terminated Phase 3 Drug / neuroprotection
- Sponsor
- R-Tech Ueno, Ltd.
- Treatment
- UF-021; Placebo
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 20 Years to 70 Years
- Enrollment
- 202 participants
- Started
- 2013-03
- Main results expected
- 2015-04
- Results posted
- Not yet
- Record last updated
- 2016-01-29
What the study is testing
This study is a multicenter trial performed in Japan, consisting of a comparative study period and a continuous administration period.
Effect of 0.15% UF-021 eye drops on improvement in central retinal sensitivity with HFA will be verified in 52 weeks comparative study period by a placebo-controlled, double-masked study in patients with retinitis pigmentosa.
The safety of same eye drops will also be examined in 52 weeks continuous administration period, in all the patients who completed the comparative study period.
Where it runs
Japan (34)
- , Nagoya, Aichi-ken
- , Hirosaki, Aomori
- , Chiba, Chiba
- , Matsuyama, Ehime
- , Fukuoka, Fukuoka
- , Maebashi, Gunma
- , Kure, Hiroshima
- , Sapporo, Hokkaido
- , Kobe, Hyōgo
- , Mito, Ibaraki
- , Morioka, Iwate
- , Kumamoto, Kumamoto
- , Kyoto, Kyoto
- , Tsu, Mie-ken
- , Sendai, Miyagi
- , Miyakonojō, Miyazaki
- , Miyazaki, Miyazaki
- , Beppu, Oita Prefecture
- , Okayama, Okayama-ken
- , Tamano, Okayama-ken
- , Osaka, Osaka
- , Sayama, Osaka
- , Izumo, Shimane
- , Hamamatsu, Shizuoka
- , Ohtawara, Tochigi
- , Tokushima, Tokushima
- , Bunkyo-ku, Tokyo
- , Chiyoda-ku, Tokyo
- , Minato-ku, Tokyo
- , Mitaka, Tokyo
- , tabashi City, Tokyo
- , Toyama, Toyama
- , Wakayama, Wakayama
- , Chūō, Yamanashi